Education
About Us
Working with TipRanks
Follow Us
Corline Biomedical AB (SE:CLBIO)
:CLBIO
CLBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr5.98 - kr16.00
Previous CloseN/A
Volume1.95K
Average Volume (3M)26.60K
Market Cap
kr363.69M
Enterprise Valuekr252.51M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Nov 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding24,490,820
10 Day Avg. Volume10,817
30 Day Avg. Volume26,601
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CLBIO FAQ
What was Corline Biomedical AB’s price range in the past 12 months?
Corline Biomedical AB lowest stock price was kr5.98 and its highest was kr16.00 in the past 12 months.
What is Corline Biomedical AB’s market cap?
Corline Biomedical AB’s market cap is kr363.69M.
When is Corline Biomedical AB’s upcoming earnings report date?
Corline Biomedical AB’s upcoming earnings report date is Nov 21, 2025 which is in 62 days.
How were Corline Biomedical AB’s earnings last quarter?
Corline Biomedical AB released its earnings results on Aug 26, 2025. The company reported -kr0.133 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.133.
Is Corline Biomedical AB overvalued?
According to Wall Street analysts Corline Biomedical AB’s price is currently Overvalued.
Does Corline Biomedical AB pay dividends?
Corline Biomedical AB does not currently pay dividends.
What is Corline Biomedical AB’s EPS estimate?
Corline Biomedical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Corline Biomedical AB have?
Corline Biomedical AB has 24,490,820 shares outstanding.
What happened to Corline Biomedical AB’s price movement after its last earnings report?
Corline Biomedical AB reported an EPS of -kr0.133 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.279%.
Which hedge fund is a major shareholder of Corline Biomedical AB?
Currently, no hedge funds are holding shares in SE:CLBIO
Company Description
Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.
Technical Analysis
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
Intervacc AB
―
Active Biotech AB
―